Book contents
- Frontmatter
- Contents
- Contributors
- Preface
- DRUG DESIGN
- 1 Progress and issues for computationally guided lead discovery and optimization
- PART I STRUCTURAL BIOLOGY
- PART II COMPUTATIONAL CHEMISTRY METHODOLOGY
- PART III APPLICATIONS TO DRUG DISCOVERY
- 12 Computer-aided drug design: a practical guide to protein-structure-based modeling
- 13 Structure-based drug design case study: p38
- 14 Structure-based design of novel P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease
- 15 Purine nucleoside phosphorylases as targets for transition-state analog design
- 16 GPCR 3D modeling
- 17 Structure-based design of potent glycogen phosphorylase inhibitors
- Index
- References
16 - GPCR 3D modeling
from PART III - APPLICATIONS TO DRUG DISCOVERY
Published online by Cambridge University Press: 06 July 2010
By
Book contents
- Frontmatter
- Contents
- Contributors
- Preface
- DRUG DESIGN
- 1 Progress and issues for computationally guided lead discovery and optimization
- PART I STRUCTURAL BIOLOGY
- PART II COMPUTATIONAL CHEMISTRY METHODOLOGY
- PART III APPLICATIONS TO DRUG DISCOVERY
- 12 Computer-aided drug design: a practical guide to protein-structure-based modeling
- 13 Structure-based drug design case study: p38
- 14 Structure-based design of novel P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease
- 15 Purine nucleoside phosphorylases as targets for transition-state analog design
- 16 GPCR 3D modeling
- 17 Structure-based design of potent glycogen phosphorylase inhibitors
- Index
- References
Summary
INTRODUCTION
G-protein-coupled receptors (GPCRs) are a superfamily of membrane proteins that provide cells with the ability to communicate with each other and their environment. The core feature of these proteins is their seven transmembrane helices (7TM) that form a bundle located in the cell membrane (Figure 16.1). The seven helices are linked together by three extracellular loops (ECLs) and three intracellular loops (ICLs) and also include N- and C-terminal regions. This 7TM region is responsible for receiving a wide range of signals from small-molecule amines, peptides, proteins, small odorant and taste molecules, and light, which either bind in the interior of the 7TM bundle or to its extracellular surface or interact with chromophores located in its interior. These external signals trigger the coupling of the ICLs (in particular ICL5) with the heterotrimeric G-protein transducin, which in turn initiates a cascade of signaling events that lead to proliferation, differentiation, development, cell survival, angiogenesis, and hypertrophy. In light of these facts it is not surprising to find that GPCRs are implicated as targets in a wide range of indications, including heart disease, allergies, depression, mental illness, cognition, and hypertension.
The estimated number of GPCRs in humans is ∼1,000 members or ∼1% of the genome. There are five major classes of GPCRs that are defined by their sequence homology and the type of endogenous ligand. The most important of these classes are A, B, and C. GPCRs are dysfunctional or dysregulated in many diseases making them the target of drug therapies.
- Type
- Chapter
- Information
- Drug DesignStructure- and Ligand-Based Approaches, pp. 248 - 256Publisher: Cambridge University PressPrint publication year: 2010
References
; Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 1999, 18, 1723.Google Scholar
; ; Target validation of G-protein coupled receptors. Drug Discov. Today 2002, 7, 235.Google Scholar
Molecular Modeling Principles and Applications. Essex, UK: Prentice Hall; 2001.
. Towards 3D Structures of G Protein-Coupled Receptors: A Multidisciplinary Approach. Curr. Med. Chem. 2000, 7, 861.Google Scholar
; ; ; Ligand identification for G-protein-coupled receptors: a lead generation perspective. Curr. Opin. Chem. Biol. 2004, 8, 287.Google Scholar
; ; Comparison of Shape-Matching and Docking as Virtual Screening Tools. J. Med. Chem. 2007, 50, 74.Google Scholar
; In: Pharmacophore Preception, Development, and Use in Drug Design, , Ed.; La Jolla, CA: International University Line; 2000, 71.
; ; ; ; ; .; ; ; .; .; ; Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor. Science 2000, 289, 739.Google Scholar
; ; Crystal Structure of Rhodopsin: A G-Protein-Coupled Receptor. ChemBioChem 2002, 3, 963.Google Scholar
; ; ; ; ; ; ; ; ; ; ; ; Crystal structure of the human β2 adrenergic G-protein-coupled receptor. Nature 2007, 450, 383.Google Scholar
; ; ; .; ; ; ; ; ; ; High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein-Coupled Receptor. Science 2007, 318, 1258.Google Scholar
; ; ; ; ; ; ; ; ; ; GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function. Science 2007, 318, 1266.Google Scholar
Comparative modeling methods: application to the family of the mammalian serine proteases. Proteins 1990, 7, 317.Google Scholar
; ; ; X-ray Structure of Bacteriorhodopsin at 2.5 Angstroms from Microcrystals Grown in Lipidic Cubic Phases. Science, 1997, 277, 1676.Google Scholar
; ; Proton transfer pathways in bacteriorhodopsin at 2.3 angstrom resolution. Science, 1998, 280, 1934.Google Scholar
; ; ; ; Structure of Bacteriorhodopsin at 1.55 Å Resolution. J. Mol. Biol., 1999, 291, 899.Google Scholar
The probable arrangement of the helices in G protein-coupled receptors. EMBO J. 1993, 12 1693.Google Scholar
; Low resolution structure of bovine rhodopsin determined by electron cryo-microscopy. Biophys. J. 1995, 68, 1776.Google Scholar
; ; ; On the use of the transmembrane domain of bacteriorhodopsin as a template for modeling the three-dimensional structure of guanine nucleotide-binding regulatory protein-coupled receptors. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 4009.Google Scholar
; ; ; Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. Mol. Pharmacol. 1991, 40, 8.Google Scholar
; Three-dimensional structure for the β2 adrenergic receptor protein based on computer modeling studies. J. Mol. Biol. 1992, 225, 859.Google Scholar
; A 3D model of the ö opioid receptor and ligand-receptor complexes. Protein Eng. 1996, 9, 573.Google Scholar
; ; ; ; Rhodopsin crystal: new template yielding realistic models of G-protein-coupled receptors?Trends Pharmacol. Sci. 2003, 24, 36.Google Scholar
; ; ; Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. Adv. Protein Chem. 2003, 63, 243.Google Scholar
; New G-protein-coupled receptor crystal structures: insights and limitations. Trends Pharmacol. Sci. 2008, 29, 79.Google Scholar
Protein homology modeling and drug discovery. In: The Practice of Medicinal Chemistry. New York, NY: Academic Press; 1996, 523–546.
; ; Homology modeling and binding site mapping of the human histamine H1 receptor Eur. J. Med. Chem. 2004, 39, 959.Google Scholar
; Three-Dimensional Models for β-Adrenergic Receptor Complexes with Agonists and Antagonists. J. Med. Chem. 2003, 46, 4450.Google Scholar
; . Structure-based Drug Discovery Using GPCR Homology Modeling: Successful Virtual Screening for Antagonists of the Alpha1A Adrenergic Receptor. J. Med. Chem. 2005, 48, 1088.Google Scholar
; ; Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore. J. Mol. Graph. Model. 2006, 24, 456.Google Scholar
. On the Applicability of GPCR Homolgy Models to Computer-Aided Drug Discovery: A Comparison between In Silico and Crystal Structures of the β2-Adrenergic Receptor. J. Med. Chem. 2008, 51, 2907.Google Scholar
; ; ; ; ; ; ; ; ; G Protein-coupled receptors: In silico drug discovery in 3D. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 11304.Google Scholar
; .; ; ; ; ; ; ; ; ; ; ; PREDICT Modeling and In-Silico Screening for G-Protein Coupled Receptors. Proteins 2004, 57, 51.Google Scholar
; ; ; ; ; ; ; Prediction of structure and function of G protein-coupled receptors. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 12627.Google Scholar
; ; ; ; Molecular mechanisms underlying differential odor responses of a mouse olfactory receptor. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 10712.Google Scholar
; Prediction of the Structure of G-Protein Coupled Receptor with Application for Drug Design. Pac. Symp. Biocomput. 2008, 13, 344.Google Scholar
; ; ; Three-Dimensional Models for Agonist and Antagonist Complexes with β2 Agrenergic Receptor. J. Med. Chem. 1996, 4406.Google Scholar
; .; ; Molecular Evolution of Adrenoceptors and Dopamine Receptors: Implications for the Binding of Catecholamines. J. Med. Chem. 2006, 49, 1706.Google Scholar
; ; ; Modeling of G-Protein-Coupled Receptors: Application to Dopamine, Adrenaline, Serotonin, Acetylcholine, and Mammalian Opsin Receptors. J. Med. Chem. 1992, 35, 3448.Google Scholar
; ; .; Protein-Based Virtual Screening of Chemical Databases. II. Are Homology Models of G-Protein Coupled Receptors Suitable Targets?Proteins 2003, 50, 5.Google Scholar
; ; ; ; .; ; ; ; ; ; ; ; Discovery of Novel Chemotypes to a G-Protein-Coupled Receptor through Ligand-Steered Homology Modeling and Structure-Based Virtual Screening. J. Med. Chem. 2008, 51, 581.Google Scholar
; ; ; ; ; ; ; ; Discovery of Novel Human Histamine H4 Receptor Ligands by Large-Scale Structure-Based Virtual Screening. J. Med. Chem. 2008, 51, 3145.Google Scholar
; .; Structure-Based Identification of Binding Sites, Native Ligands and Potential Inhibitors for G-Protein Coupled Receptors. Proteins 2008, 51, 423.Google Scholar
; ; ; ; ; ; Molecular Modeling of the Three-Dimensional Structure of Dopamine 3 (D3) Subtype Receptor: Discovery of Novel and Potent D3 Ligands through a Hybrid Pharmacophore- and Structure-Based Database Screening Approach. J. Med. Chem. 2003, 46, 4377.Google Scholar
; ; ; ; ; Identification of Nonpeptide CCR5 Receptor Agonists by Structure-based Virtual Screening. J. Med. Chem. 2007, 50, 1294.Google Scholar
; Use of the X-ray structure of the Beta2-adrenergic receptor for drug discovery. Bioorg. Med. Chem. Lett. 2008, 18, 1598.Google Scholar
; ; ; Molecular Dynamics Simulation of Dark-adapted Rhodopsin in an Explicit Membrane Bilayer: Coupling between Local Retinal and Larger Scale Conformational Change. J. Mol. Biol. 2003, 333, 493.Google Scholar
; ; ; ; Dynamic behavior of fully solvated β2-adrenergic receptor, embedded in the membrane with bound agonist or antagonist. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 4882.Google Scholar
; ; ; ; ; Probing a Model of a GPCR/Ligand Complex in an Explicit Membrane Environment: The Human Cholecystokinin-1 Receptor. Biophys. J. 2006, 90, 1232.Google Scholar
; ; ; ; ; ; Lipid Bilayer Simulations of CXCR4 with Inverse Agonists and Weak Partial Agonists. J. Biol. Chem. 2003, 278, 47136.Google Scholar
; ; Introducing an Implicit Membrane in Generalized Born/Solvent Accessibility Continuum Solvent Models. J. Phys. Chem. B 2002, 106, 8726.Google Scholar
; ; An Implicit Membrane Generalized Born Theory for the Study of Structure, Stability, and Interactions of Membrane Proteins. Biophys. J. 2003, 85, 2900.Google Scholar
; ; ; Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 1990, 112, 6127.Google Scholar
; ; ; ; ; ; ; Toward the Active Conformations of Rhodopsin and the β2-Adrenergic Receptor. Proteins 2004, 56, 67.Google Scholar
; ; ; Modeling activated states of GPCRs: the rhodopsin template. J. Comput. Aided Mol. Des. 2006, 20, 437.Google Scholar
; ; ; ; ; ; ; ; Crystal structure of a photoactivated deprotonated intermediate of rhodopsin. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 16123.Google Scholar
; .; TETHERING: Fragment-Based Drug Discovery. Annu. Rev. Biophys. Struct. 2004, 33, 199.Google Scholar